CellCarta Biosciences, Inc.
Global contract research organization (CRO) offering integrated laboratory services across immune monitoring, histopathology, proteomics, genomics, spatial and single-cell biology, bioinformatics, and sample logistics to support discovery through clinical development and companion diagnostic efforts.
Industries
N/A
Nr. of Employees
medium (51-250)
Products
Cytometry analysis software
Comprehensive cytometry analysis platform for visualization, gating and standardized reporting of cytometry datasets.
Healthy-tissue proteomic reference database
Curated healthy-tissue proteomic reference used to prioritize neo-epitopes and interpret antigen-presentation data.
Cytometry analysis software
Comprehensive cytometry analysis platform for visualization, gating and standardized reporting of cytometry datasets.
Healthy-tissue proteomic reference database
Curated healthy-tissue proteomic reference used to prioritize neo-epitopes and interpret antigen-presentation data.
Services
End-to-end development and regulatory-oriented validation of biomarker assays across multiple platforms and sample types.
Quantitative proteomics, targeted MS assays for biomarker quantification and pharmacokinetics, including affinity-reagent-free methods for ADC quantification.
Digital PCR, qPCR, RNA sequencing and next-generation sequencing workflows for mutation detection, expression profiling and molecular characterization.
Tissue-based biomarker analysis including IHC, IF, ISH, multiplex IHC and digital slide analysis provided to clinical standards.
Comprehensive immune monitoring using flow cytometry, ELISpot/FluoroSpot, basophil activation tests and mass cytometry for pharmacodynamic and biomarker endpoints.
Integrated statistical analysis, data visualization, pathway analysis and machine-learning-based exploratory analysis tailored to study objectives.
End-to-end development and regulatory-oriented validation of biomarker assays across multiple platforms and sample types.
Quantitative proteomics, targeted MS assays for biomarker quantification and pharmacokinetics, including affinity-reagent-free methods for ADC quantification.
Digital PCR, qPCR, RNA sequencing and next-generation sequencing workflows for mutation detection, expression profiling and molecular characterization.
Tissue-based biomarker analysis including IHC, IF, ISH, multiplex IHC and digital slide analysis provided to clinical standards.
Comprehensive immune monitoring using flow cytometry, ELISpot/FluoroSpot, basophil activation tests and mass cytometry for pharmacodynamic and biomarker endpoints.
Integrated statistical analysis, data visualization, pathway analysis and machine-learning-based exploratory analysis tailored to study objectives.
Expertise Areas
- Biomarker development and regulatory validation
- Proteomics and quantitative mass spectrometry
- Immune monitoring and cellular phenotyping
- Genomics, qPCR and next-generation sequencing
Key Technologies
- Targeted mass spectrometry (MRM) and discovery proteomics
- Multiparametric flow cytometry and cell sorting
- Mass cytometry (high-parameter single-cell proteomics)
- ELISpot / FluoroSpot and intracellular cytokine staining (ICS)
News & Updates
Presence and meeting bookings at the Society for Immunotherapy of Cancer (SITC) conference.
Announcement of a strategic collaboration to co-promote development of companion diagnostics.
Launch of a Chinese mobile website and WeChat mini-program to support local stakeholders.
Publication of a Phase I clinical study of a heterobifunctional degrader in advanced synovial sarcoma and SMARCB1-deficient tumors.
Opened a CAP-accredited laboratory in Jining (2019) offering flow cytometry, histopathology, genomics and immunoassays and local regulatory support.
Presence and meeting bookings at the Society for Immunotherapy of Cancer (SITC) conference.
Announcement of a strategic collaboration to co-promote development of companion diagnostics.
Launch of a Chinese mobile website and WeChat mini-program to support local stakeholders.
Publication of a Phase I clinical study of a heterobifunctional degrader in advanced synovial sarcoma and SMARCB1-deficient tumors.
Opened a CAP-accredited laboratory in Jining (2019) offering flow cytometry, histopathology, genomics and immunoassays and local regulatory support.